

CP1654

The

Application No. (if known): 09/762,067

Attorney Docket No.: 01946/100D864-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EU 382051866 - US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	November 18, 2004
	Date

	B.W. Lee					
	Signatui	e				
	B.WC	ε ε.				
	Typed or printed name of per	son signing Certificate				
Regi	stration Number, if applicable	Telephone Number				
Note:	Each paper must have its own certificate of each submitted paper. Fee Transmittal for FY 2005 (1 page); Information Disclosure Statement (2 p List of References (PTO\SB08a\b form 2 Patent Documents; 8 Publications;	ages);				

Postcard; and Check No. 677.5 for \$ 180.00

PTO/SB/17 (10-04) ed for use through 7/31/2006. OMB 0651-0032

Victor the Papenyon Deduction Act of 1995, no person are requ	ired to	respond	U.S. P	atent ar	Appro nd Tradem of informati	ark Office; U.S. DEPARTMENT OF (on unless it displays a valid OMB cor	COMMERCE
TRIVE		С			Com	plete if Known	
FEETRANSMITTAL	,	Appli	cation	Numb		09/762,067	-
for EV 2005		Filing			-	August 3, 2001	
for FY 2005			Named	Inver	itor	David Gschneidner et al.	
Effective 10/01/2004. Patent fees are subject to annual revision.			iner Na		1.01	Maury Audet	
Applicant claims small entity status. See 37 CFR 1.27		Art Ur	nit			1654	
TOTAL AMOUNT OF PAYMENT (\$) 180.00		Attorn	ey Doo	cket No) .	01946/100D864-US1	
METHOD OF PAYMENT (check all that apply)	Γ		-	FEE	CALCU	LATION (continued)	
Chack Credit Money Chack Name	2.	DDITI	ONAL			· · · · · · · · · · · · · · · · · · ·	
Cireck Card Order Order	"	100111	UNAL	LLS	'		
Deposit Account:			0				
Deposit Account 04-0100	Fee	Entity Fee	Fee	Entity	=		
Number	Code	(\$)	Code	(\$)		Fee Description	Fee Pald
Deposit Account Darby & Darby P.C.	1051	130	2051	65	Surcharge	e - late filing fee or oath	
Name The Director is authorized to: (check all that apply)	1052	50	2052	25		e – late provisional filing fee or cover	
	4050	400		400	sheet.		
Charge fee(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-Engl	sh specification	
Charge any additional fee(s) or any underpayment of fee(s)	1812	2,520	1812	2,520	_	request for ex parte reexamination	
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1804	920*	1804	920*	Requestir Examiner	ng publication of SIR prior to action	
	1805	1,840*	1805	1,840*	Requestir Examiner	ng publication of SIR after action	
FEE CALCULATION	1251	110	2251	55	Extension	for reply within first month	
1. BASIC FILING FEE	1252	430	2252	215	Extension	for reply within second month	
Large Entity Small Entity	1253	980	2253	490	Extension	for reply within third month	
Fee Fee Fee Fee Fee Paid Code (\$) Code (\$)	1254	1,530	2254	765	Extension	for reply within fourth month	
1001 790 2001 395 Utility filing fee	1255	2,080	2255	1,040	Extension	for reply within fifth month	
1002 350 2002 175 Design filing fee	1401	340	2401	170	Notice of	Арреаі	
1003 550 2003 275 Plant filing fee	1402	340	2402	170	Filing a br	ief in support of an appeal	
1004 790 2004 395 Reissue filing fee	1403	300	2403	150	•	or oral hearing	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451			institute a public use proceeding	
SUBTOTAL (1) (\$) 0.00	1452 1453	110	2452	55 685		revive – unavoidable	
A EVERA OLANA ESSA SOR UELLEY AND DEIROUE	1501	1,370	2501	685		revive - unintentional re fee (or reissue)	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Extra Fee from	1501	1,370 490	2502		•	, ,	
Total Claims below Fee Paid				245	Design is:		
Independent Indepe	1503 1460	660 130	2503 1460	330 130	Plant issu	e ree to the Commissioner	
Claims X X							
Multiple Dependent	1807	50	1807	50		ig fee under 37 CFR 1.17(q)	
Large Entity Small Entity	1806	180	1806	180		on of Information Disclosure Strnt	180.00
Fee Fee Fee Code (\$) Code (\$) Fee Description	8021	40	8021	40		geach patent assignment per times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	790	2809	395	Filing a st	ubmission after final rejection	
1201 88 2201 44 Independent claims in excess of 3	1810	790	2810	395	For each	additional invention to be	
1203 300 2203 150 Multiple dependent claim, if not paid 1204 88 2204 44 ** Reissue independent claims		790	2801			(37CFR 1.129(b))	
over original patent	1801			395	•	or Continued Examination (RCE) or expedited examination	\vdash
1205 18 2205 9 ** Reissue claims in excess of 20	1802	900	1802	900		n application	
and over original patent	Other	fee (spe	cify)				
SUBTOTAL (2) (\$) 0.00	*Redu	uced by I	Basic Fi	ling Fee	Paid	SUBTOTAL (3) (\$)	180.00
**or number previously paid, if greater; For Reissues, see above	<u> </u>						

SUBMITTED BY	(Complete (if applicable))		
Name (Print/Type) Jason C. Chumney	Registration No. (Attorney/Agent) 54,781	Telephone	(212) 527-7700
Signature		Date	November 18, 2004
0			

Express Mail Label No.	Dated:		

Docket No.: 01946/100D864-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

David Gschneidner et al.

Application No.: 09/762,067 Confirmation No.: 7883

Filed: August 3, 2001 Art Unit: 1654

For: COMPOUNDS AND COMPOSITIONS FOR

DELIVERING ACTIVE AGENTS

Examiner: Maury Audet

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as

{W:\01946\100d864us1\00294331.DOC | 運動運動的工程網刊工程網刊工程網刊工工 }

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

By

Dated: November 18, 2004

Respectfully submitted,

Jason C. Chumney

Registration No.: \$4,781 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03) Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of Contract of Contr

required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	09/762,067	
11	NFORMATION	I DI	SCLOSURE	Filing Date	August 3, 2001	
S	STATEMENT BY APPLICANT			First Named Inventor	David Gschneidner et al.	
(Use as many sheets as necessary)				Art Unit	1654	
			necessary)	Examiner Name	Maury Audet	
Sheet	1	of	1	Attorney Docket Number	01946/100D864-US1	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Traine of Fateritee of	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.'	Number-Kind Code ⁴ (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
	AA	US-3,489,793	07/13/1970	Bertelli, et al.	Entire document	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
	BA	ES 369853	07/24/1069	Laboratorios Bama	Entire document	X	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	O'Shaughnessy, Catherine, et al. "Acylated Non-Alpha-Amino Acids Increase the Permeation of Recombinant Human Growth Hormone Through CACO-2 Monolayers", Abstract 1997 AAPS Annual Meeting Abstracts, November 1997.	
	СВ	O'Shaughnessy, Catherine. "Acylated Non-Alpha-Amino Acids Increase the Permeation of Recombinant Human Growth Hormone Through CACO-2 Monolayers". Poster Presentation at 1997 AAPS Annual Meeting. November 1997.	
	CC	O'Shaughnessy, Catherine, et al. "Acylated Non-Alpha-Amino Acids Increase the Permeation of Horseradish Peroxidase Through CACO-2 Monolayers", Abstract 1997 AAPS Annual Meting Abstracts. November 1998.	
	CD	Freeman, John, et al., "The Use of Parallel Synthesis to Prepare Compounds For An <i>In Vivo</i> Assay". Poster Presentation at 217th American Chemical Society Meeting, March 21, 1999.	
	CE	Freeman, John, et al., "The Use of Parallel Synthesis to Prepare Compounds For An <i>In Vivo</i> Assay". Abstract. American Chemical Society, March 21, 1999.	
	CF	O'Toole, Doris, et al., "Increased Throughput in an <i>In Vivo</i> Assay by Use of Parallel Synthesis Array. Abstract 1998 AAPS Annual Meeting Abstracts. November 1998.	
	CG	O'Toole, Doris, et al., "Increased Throughput in an <i>In Vivo</i> Assay by Use of Parallel Synthesis Array. Poster Presentation at 1998 AAPS Annual Meeting, Anaheim, California. November 16, 1998.	
	СН	Leone-Bay, Andrea, et al. "Oral Delivery of Biologically Active Parathyroid Hormone. Pharmaceutical Research. Vol. 18(7):964-970. 2001.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	 	
[{W:\019	Date	
1/44.10131	Date	1
140/4004	Considered	i
46/1004	Considered	

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.